Gemfibrozil therapy alone can induce severe myopathy and rhabdomyolysis. This catastrophic complication had been frequently reported in renal failure patients. Dosage reduction is therefore compulsory in patients with compromised renal function, no matter which type of renal replacement therapy they receive. This study's patient clearly demonstrates that gemfibrozil can induce severe rhabdomyolysis, even in patients receiving CVVH, if the dosage is not properly adjusted.
- Acute renal failure
- Continuous veno-venous hemofiltration
ASJC Scopus subject areas